Dr. Leapman on Factors Influencing the Decision to Undergo Genomic Testing in Prostate CancerFebruary 23rd 2023
Michael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.
Dr. Grivas on the Real-World Study of Avelumab Maintenance in Metastatic Urothelial CarcinomaFebruary 23rd 2023
Petros Grivas, MD, PhD, discusses key baseline characteristics from the real-world PATRIOT II study of first-line avelumab maintenance therapy in metastatic urothelial cancer.
Nivolumab Plus Salvage Immunotherapy Leads to High TFS Rates in Advanced RCCFebruary 21st 2023
Nivolumab monotherapy, plus salvage nivolumab plus ipilimumab for progressive disease, resulted in high treatment-free survival rates in patients with previously untreated advanced clear cell renal cell carcinoma.
First-line Avelumab Maintenance Under Real-world Evaluation in Metastatic Urothelial Carcinoma
The baseline characteristics, treatment patterns, and responses to first-line platinum-based chemotherapy for patients with locally advanced or metastatic urothelial carcinoma receiving avelumab maintenance therapy were consistent with responses to usual therapy paradigms in the first-line induction setting.
Avelumab Efficacy Holds-Up In A Real-World Analysis of Patients With Locally Advanced, Metastatic Urothelial CarcinomaFebruary 20th 2023
The efficacy profile for avelumab in patients with locally advanced or metastatic urothelial carcinoma was consistent in a real-world setting with what had been reported in the phase 3 JAVELIN Bladder 100 trial.
Dr. Albigès on the CaboPoint Trial in Advanced RCCFebruary 18th 2023
Laurence Albigès, MD, PhD, discusses the main objective and trial design of the phase 2 CaboPoint study in renal cell carcinoma, as well as key efficacy and safety data reported in an interim analysis of this study.
Atezolizumab/Chemotherapy Trends Toward Improved OS in Urothelial CarcinomaFebruary 18th 2023
First-line atezolizumab plus platinum-based chemotherapy and gemcitabine trended toward improved overall survival compared with placebo plus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.
Atezolizumab Monotherapy Falls Short in Exploratory OS Analysis in Untreated Locally Advanced or Metastatic Urothelial CancerFebruary 18th 2023
Atezolizumab monotherapy failed to show an improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.
Niraparib Plus Abiraterone/Prednisone Maintains rPFS Benefit in HRR Gene–Altered mCRPCFebruary 17th 2023
The combination of niraparib, abiraterone acetate, and prednisone produced prolonged survival and delayed progression rates in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
Dr. Aggarwal on Characteristics Associated With PSA PFS from the PRESTO Trial in Prostate CancerFebruary 17th 2023
Rahul Aggarwal, MD, discusses the association between baseline characteristics and prostate-specific antigen progression-free survival in patients with high-risk biochemically relapsed prostate cancer from the phase 3 PRESTO trial.
Ra-223 Displays Efficacy, Safety in mCRPC With Bone MetastasesFebruary 17th 2023
Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.
Sacituzumab Govitecan Benefit Is Consistent Following CPI in Platinum-Ineligible mUCFebruary 17th 2023
Treatment with the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan elicited an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer following progression on an immune checkpoint inhibitor, according to the primary analysis of TROPHY-U-01 cohort 2.
Potential Biomarkers of Response Identified for Enfortumab Vedotin in Advanced Urothelial CancerFebruary 17th 2023
Tumor mutational burden and alterations in CDKN2A, CDKN2B, and MTAP were among several biomarkers that were predictive of response to enfortumab vedotin in patients with advanced urothelial carcinoma, according to findings from a retrospective analysis.
Darolutamide Demonstrates Long-term Safety in nmCRPCFebruary 16th 2023
Darolutamide maintained an acceptable long-term safety profile in patients with nonmetastatic castration-resistant prostate cancer, with approximately 30% of patients remaining on the treatment for at least 4 years
Lutetium 177 PSMA-617 Following Radium-223 Is Active and Safe in mCRPCFebruary 16th 2023
Sequencing treatment with Lutetium 177 PSMA-617 after radium-223 was safe and well tolerated and demonstrated similar overall survival in patients with metastatic castration-resistant prostate cancer regardless of whether they received 177Lu-PSMA-617 within 6 months or after 6 months of completing radium-223.
Dr. Tombal on the OS Benefit of Darolutamide Plus ADT/Docetaxel in mHSPCFebruary 16th 2023
Bertrand Tombal, MD, PhD, discusses the overall survival benefit associated with androgen-deprivation therapy plus darolutamide in metastatic hormone-sensitive prostate cancer.
Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPCFebruary 16th 2023
The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.
Darolutamide Demonstrates Favorable Tolerability, Decreased Metastatic Progression in nmCRPCFebruary 16th 2023
Treatment with darolutamide decreased the likelihood of developing metastatic disease or discontinuing treatment because of adverse effects vs treatment with apalutamide or enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
Adjuvant Mitotane Fails to Improve RFS in Patients with ACC at Low/Intermediate Risk of Recurrence
The utilization of mitotane in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma at low or intermediate risk of recurrence.